For research use only
| Cat No. | ABC-TC0005 |
| Product Type | Human Bladder Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Bladder Cancer |
| Product Code | 253j; 253-J; 253 J; 253J-P; 253J-Parental; 253J P; 253JP |
Tumorigenecity: Isoenzyme: Histopathology: bladder cancerSubculture: Split ratio: Media change: Reverse transcritase: Production
253J is a human transitional cell carcinoma (TCC) cell line originally derived from a grade II bladder tumor of a 53-year-old Caucasian male patient. This parental line is part of a widely used matched model system for studying bladder cancer progression and metastasis. 253J cells exhibit epithelial morphology with polygonal shape and form adherent monolayers under standard culture conditions. Cytogenetically, 253J cells are aneuploid with multiple chromosomal abnormalities characteristic of bladder carcinoma. These cells express markers typical of urothelial origin, including uroplakin and E-cadherin, and retain epithelial differentiation features. The cell line is tumorigenic in immunodeficient mice, forming subcutaneous tumors without spontaneous metastasis, distinguishing it from its metastatic variant 253J-BV. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | 253j; 253-J; 253 J; 253J-P; 253J-Parental; 253J P; 253JP |
| Species | Human |
| Cat.No | ABC-TC0005 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Bladder Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bladder Cancer Cell Lines |
| Stock | Out of stock |
253J cells provide a reliable in vitro model for investigating non-metastatic bladder cancer biology. They are widely employed in studies of cell adhesion, epithelial-to-mesenchymal transition (EMT), chemotherapy resistance, and urothelial carcinogenesis. Additionally, 253J is frequently used in matched-pair experimental designs to compare with metastatic derivatives for understanding molecular events underlying cancer progression and therapeutic targeting.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
